ClinicalTrials.gov
ClinicalTrials.gov Menu

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02933736
Recruitment Status : Recruiting
First Posted : October 14, 2016
Last Update Posted : January 6, 2017
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Madelon Petersen, St. Joseph's Hospital and Medical Center, Phoenix

Brief Summary:
In the proposed trial, patients will be administered ribociclib prior to surgical resection of their tumor. Patients will be enrolled in time-intervals sequentially (non-randomized). All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 intervals before brain tumor resection.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Meningioma Drug: Ribociclib Early Phase 1

Detailed Description:

900 mg/d is the maximally tolerated dose (MTD), as determined in a recent Novartis-sponsored Phase I study for advanced solid tumor patients. The recommended dose expansion and Phase 2 is 600mg/d for 3 weeks on and 1 week off. Due to drug pharmacokinetics, the MTD (900mg) dose will be used for pre-surgical dosing in order to maximize the opportunity to identify relevant tumor pharmacokinetic and pharmacodynamics endpoints.

To assess the PK, PD, and PG endpoints listed above, CSF and brain tumor tissue will be collected intraoperatively (for gliomas, enhancing and non-enhancing tumor tissue will be collected and analyzed separately). Additionally, blood samples will be obtained at 0.5, 1, 2, 4, 6, 8, and 24 hours after the final ribociclib dose is administered.

Patients with tumors demonstrating positive PK, PD, and PG effects will continue treatment with ribociclib (21 days on, 7 days off) after surgery. This will constitute the Phase II component of the study. Patients will be treated until unacceptable toxicity is observed, or until disease progression as assessed by radiographic or clinical metrics. Preliminary rates of progression-free survival in patients with high-grade gliomas and high-grade meningiomas treated with ribociclib will be measured through radiographic and clinical response metrics, specifically Response Assessment in Neuro-Oncology (RANO) criteria and investigator discretion. Overall survival in patients with high-grade gliomas and high-grade meningiomas treated with ribociclib will be assessed by medical record review and survival follow up. Common Toxicity Criteria Adverse Event (CTC AE 4.0) will be utilized to review ribociclib treatment effects in patients with brain tumors. The trough plasma samples of ribociclib will be collected at pre-dosing on each clinical visit day (e.g., days 1, 22, 43, 64...) prior to the administration of ceritinib on that day. Ribociclib will be administered in the clinics on the clinic visit days to ensure the collection of trough level samples.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 0/II Study of Ribociclib (LEE011) in Preoperative Rb-Positive Recurrent High-Grade Glioma and Meningioma Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
Study Start Date : October 2016
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : April 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Ribociclib

Arm Intervention/treatment
Experimental: Administration of ribociclib

Subjects will be administered ribociclib prior to surgical resection of their tumor. Ribociclib administration will occur at sequential time-intervals (i.e.,Cohort 1 will be filled first with 16 subjects, then Cohort 2 the same, followed by Cohort 3). All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 following intervals before brain tumor resection:

Cohort 1: last ribociclib dose 2-4 hours prior to craniotomy for tumor resection

Cohort 2: last ribociclib dose 4-8 hours prior to craniotomy for tumor resection

Cohort 3: last ribociclib dose 22-26 hours prior to craniotomy for tumor resection

Drug: Ribociclib
Other Name: LEE011




Primary Outcome Measures :
  1. Plasma Exposure [ Time Frame: 0.5, 1, 2, 4, 6, 8, and 24 hours post-last 900 mg dosing ]
  2. CSF Penetration [ Time Frame: 2-4, 6-8, and 23-25 hours post-last 900 mg dosing ]
  3. Brain Accumulation of Ribociclib [ Time Frame: Days 1, 22, 43, 64 (add 21 day intervals)...until disease returns or side effect preventing participation in study occurs ]
    This is the Phase II portion, which assesses trough plasma concentrations of study drug on each clinical visit day, prior to administration of ribociclib on that day.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • One prior resection of histologically-diagnosed WHO Grade III or IV glioma, or WHO grade II or III meningioma.
  • MRI evidence of disease recurrence
  • For gliomas, archival tissue much demonstrate (a) RB positivity on immunohistochemistry OR no RB mutations on next-gen sequencing (NGS), (b) Chromosome 9p21.3 deletion on FISH OR CDKN2A/B/C loss on array CGH.
  • For meningiomas, archival tissue much demonstrate (a) RB positivity on immunohistochemistry OR no RB mutations on next-gen sequencing (NGS).
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2
  • Patients ≥ 18 years of age
  • Ability to understand and the willingness to sign a written informed consent document.
  • Patient has voluntarily agreed to participate by giving written informed consent.

(Written informed consent for the protocol must be obtained prior to any screening procedures. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness.)

  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other procedures.
  • Patients must have recovered from all toxicities related to prior anticancer therapies to ≤ grade 2 (CTCAE v 4.03), provided that concomitant medication is given prior to initiation of treatment with ribociclib. Exception to this criterion: patients with any grade of alopecia are allowed to enter the treatment.
  • The following laboratory criteria have been met:

    • Absolute neutrophil count (ANC) ≥1.5 x 109/L
    • Hemoglobin (Hgb) ≥ 9 g/dL
    • Platelets ≥100 x 109/L
    • Potassium, total calcium (corrected for serum albumin), magnesium, and sodium within normal limits for the institution or corrected to within normal limits with supplements before first dose of study medication.
    • INR ≤1.5
    • Serum creatinine < 1.5 mg/dL or creatinine clearance > 50 mL/min
    • In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN. If the patient has liver metastases, ALT and AST < 5 x ULN
  • Serum total bilirubin < ULN, or < 3.0 x ULN in patients with well-documented Gilbert's syndrome.Patient with available standard 12-lead ECG with the following parameters at screening (defined as the mean of the triplicate ECGs):

    • QTcF interval at screening < 450 msec (using Fridericia's correction)
    • Resting heartrate 50-90 bpm
  • Must be able to swallow ribociclib capsules/tablets

Exclusion Criteria:

  • Archival tissue not available for research use.
  • Archival tumor not Rb-positive status
  • No prior radiotherapy
  • Co-morbid condition(s) that, at the opinion of the investigator, prevent safe surgical treatment
  • Active infection or fever > 38.5°C
  • Patients with known hypersensitivity to any of the excipients of ribociclib
  • Prior therapy with ribociclib.
  • Patient has a concurrent malignancy or malignancy within 3 years prior to starting study drug, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
  • History of HIV infection.
  • Other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol.
  • Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormalities.
  • Currently receiving any of the following medications and cannot be discontinued 7 days prior to starting study drug:

    • Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges
    • That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5
    • Herbal preparations/medications, dietary supplements.
  • Currently receiving or has received systemic corticosteroids ≤2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment. (The following uses of corticosteroids are permitted: single doses, topical applications, inhaled sprays, eye drops or local injections
  • Currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed.
  • Participation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.
  • Major surgery within 14 days prior to starting study drug or has not recovered from major side effects.
  • Has not recovered from all toxicities related to prior anticancer therapies to NCI-CTCAE version 4.03 Grade <1 (Exception: alopecia).
  • Child-Pugh score B or C.
  • History of non-compliance to medical regimen or inability to grant consent.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.]
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 3 months after the last dose of study treatment. Highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    • Male sterilization (at least 6 months prior to screening) with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate. For female subjects on the study the vasectomized male partner should be the sole partner for that subject.
    • Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
    • In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
    • Note: Oral contraceptives are allowed but should be used in conjunction with a barrier method of contraception due to unknown effect of drug-drug interaction.

Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

- Sexually active males unless they use a condom during intercourse while taking drug and for 21 days after stopping treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02933736


Contacts
Contact: Norissa Honea, RN, PhD 602-406-6267 norissa.honea@dignityhealth.org

Locations
United States, Arizona
Barrow Brain and Spine Recruiting
Phoenix, Arizona, United States, 85013
Contact: Norissa Honea, RN, PhD    602-406-6267    norissa.honea@dignityhealth.org   
Principal Investigator: Nader Sanai, MD         
Sponsors and Collaborators
St. Joseph's Hospital and Medical Center, Phoenix
Novartis
Investigators
Principal Investigator: Nader Sanai, MD Barrow Brain and Spine

Responsible Party: Madelon Petersen, Research Clinician, St. Joseph's Hospital and Medical Center, Phoenix
ClinicalTrials.gov Identifier: NCT02933736     History of Changes
Other Study ID Numbers: PHX-16-0116-80-12
First Posted: October 14, 2016    Key Record Dates
Last Update Posted: January 6, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Glioblastoma
Meningioma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Vascular Tissue
Meningeal Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases